Research programme: PCSK 9 inhibitors - Pfizer/ University of Queensland Institute for Molecular Bioscience

Drug Profile

Research programme: PCSK 9 inhibitors - Pfizer/ University of Queensland Institute for Molecular Bioscience

Alternative Names: PCSK 9 vaccine - Pfizer

Latest Information Update: 02 Mar 2015

Price : $50

At a glance

  • Originator Pfizer; University of Queenslands Institute for Molecular Bioscience
  • Class Peptides; Small molecules; Vaccines
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Lipid metabolism disorders

Most Recent Events

  • 13 Jan 2015 Preclinical trials in Cardiovascular disorders in USA (Parenteral)
  • 13 Jan 2015 Preclinical trials in Cardiovascular disorders in USA (PO)
  • 13 Jan 2015 Preclinical trials in Lipid metabolism disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top